JP7128969B2 - Ｐｃｓｋ９阻害剤及びその使用方法 - Google Patents

Ｐｃｓｋ９阻害剤及びその使用方法 Download PDF

Info

Publication number
JP7128969B2
JP7128969B2 JP2021541173A JP2021541173A JP7128969B2 JP 7128969 B2 JP7128969 B2 JP 7128969B2 JP 2021541173 A JP2021541173 A JP 2021541173A JP 2021541173 A JP2021541173 A JP 2021541173A JP 7128969 B2 JP7128969 B2 JP 7128969B2
Authority
JP
Japan
Prior art keywords
disclosed
prepared
pat
mmol
amino
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2021541173A
Other languages
English (en)
Japanese (ja)
Other versions
JP2022518015A5 (https=
JP2022518015A (ja
Inventor
エイチ セラノ－ウ，マイケル
チェンバーズ，マーク
ゴールドスミス，エリカ
ティアニー，ジェイソン
ジャンドゥ，カラミジット
クラーク，デイビッド
ヒンクリフ，ポール
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
AstraZeneca AB
Original Assignee
AstraZeneca AB
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=71613436&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=JP7128969(B2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by AstraZeneca AB filed Critical AstraZeneca AB
Publication of JP2022518015A publication Critical patent/JP2022518015A/ja
Priority to JP2022080749A priority Critical patent/JP2022116083A/ja
Publication of JP2022518015A5 publication Critical patent/JP2022518015A5/ja
Application granted granted Critical
Publication of JP7128969B2 publication Critical patent/JP7128969B2/ja
Priority to JP2024208167A priority patent/JP2025041641A/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
    • C07D239/72—Quinazolines; Hydrogenated quinazolines
    • C07D239/78—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in position 2
    • C07D239/84—Nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/10—Spiro-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/10—Spiro-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/10—Spiro-condensed systems
    • C07D491/107—Spiro-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/10—Spiro-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/05—Isotopically modified compounds, e.g. labelled

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Epidemiology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pyridine Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
JP2021541173A 2019-01-18 2020-01-16 Ｐｃｓｋ９阻害剤及びその使用方法 Active JP7128969B2 (ja)

Priority Applications (2)

Application Number Priority Date Filing Date Title
JP2022080749A JP2022116083A (ja) 2019-01-18 2022-05-17 Ｐｃｓｋ９阻害剤及びその使用方法
JP2024208167A JP2025041641A (ja) 2019-01-18 2024-11-29 Ｐｃｓｋ９阻害剤及びその使用方法

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962794234P 2019-01-18 2019-01-18
US62/794,234 2019-01-18
PCT/US2020/013881 WO2020150473A2 (en) 2019-01-18 2020-01-16 Pcsk9 inhibitors and methods of use thereof

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2022080749A Division JP2022116083A (ja) 2019-01-18 2022-05-17 Ｐｃｓｋ９阻害剤及びその使用方法

Publications (3)

Publication Number Publication Date
JP2022518015A JP2022518015A (ja) 2022-03-11
JP2022518015A5 JP2022518015A5 (https=) 2022-05-26
JP7128969B2 true JP7128969B2 (ja) 2022-08-31

Family

ID=71613436

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2021541173A Active JP7128969B2 (ja) 2019-01-18 2020-01-16 Ｐｃｓｋ９阻害剤及びその使用方法
JP2022080749A Pending JP2022116083A (ja) 2019-01-18 2022-05-17 Ｐｃｓｋ９阻害剤及びその使用方法
JP2024208167A Pending JP2025041641A (ja) 2019-01-18 2024-11-29 Ｐｃｓｋ９阻害剤及びその使用方法

Family Applications After (2)

Application Number Title Priority Date Filing Date
JP2022080749A Pending JP2022116083A (ja) 2019-01-18 2022-05-17 Ｐｃｓｋ９阻害剤及びその使用方法
JP2024208167A Pending JP2025041641A (ja) 2019-01-18 2024-11-29 Ｐｃｓｋ９阻害剤及びその使用方法

Country Status (34)

Country Link
US (2) US11248001B2 (https=)
EP (2) EP3911648B1 (https=)
JP (3) JP7128969B2 (https=)
KR (2) KR20250172693A (https=)
CN (5) CN119119022A (https=)
AU (1) AU2020209215B2 (https=)
BR (1) BR112021013807A2 (https=)
CA (1) CA3125765A1 (https=)
CL (1) CL2021001859A1 (https=)
CO (1) CO2021010312A2 (https=)
CR (1) CR20210441A (https=)
DK (1) DK3911648T3 (https=)
DO (1) DOP2021000150A (https=)
EA (1) EA202191892A1 (https=)
EC (1) ECSP21060240A (https=)
ES (1) ES3007652T3 (https=)
FI (1) FI3911648T3 (https=)
HR (1) HRP20241674T1 (https=)
HU (1) HUE069590T2 (https=)
IL (1) IL284640B2 (https=)
JO (1) JOP20210193A1 (https=)
LT (1) LT3911648T (https=)
MA (1) MA54261B1 (https=)
MX (1) MX2021008533A (https=)
PE (1) PE20220138A1 (https=)
PH (1) PH12021551686A1 (https=)
PL (1) PL3911648T3 (https=)
PT (1) PT3911648T (https=)
RS (1) RS66416B1 (https=)
SG (1) SG11202107614PA (https=)
SI (1) SI3911648T1 (https=)
SM (1) SMT202500013T1 (https=)
TW (2) TW202446767A (https=)
WO (1) WO2020150473A2 (https=)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP7558942B2 (ja) 2018-11-30 2024-10-01 コメット セラピューティクス インコーポレイテッド パンテテイン誘導体及びその使用
MX2021008661A (es) * 2019-01-18 2021-08-19 Astrazeneca Ab Inhibidores de la pcsk9 y metodos de uso de los mismos.
BR112021013807A2 (pt) 2019-01-18 2021-11-30 Astrazeneca Ab Inibidores de pcsk9 e seus métodos de uso
CN113248501B (zh) * 2021-06-17 2021-10-08 南京韦尔优众医药有限公司 Cly系列化合物及其制备方法和制备药物的用途
US20250026719A1 (en) * 2021-07-06 2025-01-23 Shengke Pharmaceuticals (Jiangsu) Ltd. Novel compounds as inhibitors of pcsk9
WO2023084449A1 (en) 2021-11-12 2023-05-19 Novartis Ag Diaminocyclopentylpyridine derivatives for the treatment of a disease or disorder
US12084453B2 (en) 2021-12-10 2024-09-10 Incyte Corporation Bicyclic amines as CDK12 inhibitors
CN114890988A (zh) * 2022-04-28 2022-08-12 浙江工业大学 一种沙利度胺的化学合成方法
EP4554939A1 (en) * 2022-07-13 2025-05-21 Astrazeneca AB Pcsk9 inhibitors and methods of use thereof
US20240217951A1 (en) 2022-09-23 2024-07-04 Astrazeneca Ab Pcsk9 inhibitors and methods of use thereof
US20240228469A1 (en) 2022-09-23 2024-07-11 Astrazeneca Ab Pcsk9 inhibitors and methods of use thereof
CN120019043B (zh) * 2022-10-14 2026-04-03 上海翰森生物医药科技有限公司 含氮杂环类衍生物抑制剂、其制备方法和应用
US20240239767A1 (en) 2022-12-16 2024-07-18 Astrazeneca Ab Pcsk9 inhibitors and methods of use thereof
CN118496204B (zh) * 2023-02-14 2025-10-24 深圳信立泰药业股份有限公司 一种氘代吡啶酮化合物及其制备方法与应用
CN119264042A (zh) * 2023-07-04 2025-01-07 上海翰森生物医药科技有限公司 含环戊烷类衍生物抑制剂、其制备方法和应用
TW202506682A (zh) 2023-07-27 2025-02-16 大陸商上海拓界生物醫藥科技有限公司 二胺基環戊基取代的雜芳基衍生物及其用途和製備方法
WO2025045777A1 (en) * 2023-08-25 2025-03-06 Draupnir Bio Aps Inhibitors of pcsk9
CN120398916A (zh) * 2023-09-25 2025-08-01 深圳信立泰药业股份有限公司 一种式(c)的吡啶酮类化合物及其制备方法与应用
WO2025168652A1 (en) 2024-02-05 2025-08-14 Astrazeneca Ab Azd-0780 in combination with a statin for use in lowering ldl-c levels and treating cardiovacular diseases
WO2025168614A1 (en) * 2024-02-05 2025-08-14 Astrazeneca Ab Pharmaceutical compositions comprising azd0780
TW202602886A (zh) 2024-03-20 2026-01-16 瑞典商阿斯特捷利康公司 Ｐｃｓｋ９抑制劑及其使用方法
TW202602866A (zh) 2024-03-20 2026-01-16 瑞典商阿斯特捷利康公司 Ｐｃｓｋ９抑制劑及其使用方法
TW202539678A (zh) 2024-03-20 2025-10-16 瑞典商阿斯特捷利康公司 Ｐｃｓｋ９抑制劑及其使用方法
WO2025214500A1 (zh) * 2024-04-12 2025-10-16 上海翰森生物医药科技有限公司 含氮杂环类衍生物的自由碱晶型和酸式盐及其晶型、其制备方法和应用
WO2025238159A1 (en) 2024-05-16 2025-11-20 Astrazeneca Ab Combination therapy comprising azd0780 and ezetimibe
WO2026021380A1 (zh) * 2024-07-22 2026-01-29 深圳信立泰药业股份有限公司 PCSK9和HMG-CoA双靶化合物与应用
CN121773107A (zh) * 2024-07-30 2026-03-31 成都施贝康生物医药科技有限公司 一种杂环衍生物抑制剂及其制备和用途
WO2026044073A1 (en) 2024-08-22 2026-02-26 Avioris Bio, Inc. Pcsk9 inhibitors and methods of using the same

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2008502736A (ja) 2004-06-09 2008-01-31 アバニール・ファーマシューティカルズ 高脂血症および関連疾患の治療のための複素環式誘導体
JP2011501952A (ja) 2007-10-26 2011-01-20 シェーリング コーポレイション 脂質障害およびコレステロール障害を治療するための抗ｐｃｓｋ９および方法
WO2011152508A1 (ja) 2010-06-04 2011-12-08 興和株式会社 光学活性ジベンジルアミン誘導体及びその製造方法
JP2022518016A (ja) 2019-01-18 2022-03-11 アストラゼネカ・アクチエボラーグ Ｐｃｓｋ９阻害剤及びその使用方法

Family Cites Families (524)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US267A (en) 1837-07-11 Mcode of hanging ob suspending a band-wheel in those hobse-powebs in
US3164588A (en) 1965-01-05 Hjnsoj
US3962A (en) 1845-03-21 Fowler m
US3009911A (en) 1961-11-21 Derivatives of j
SE168308C1 (https=)
US2661372A (en) 1953-12-01 Pharmacologically valuable stereo
US3935A (en) 1845-02-28 Improvement in machines for cutting sausage-meat
US3562A (en) 1844-04-25 Improvement in seed-planters
US3108097A (en) 1963-10-22 Ehnojs
US30577A (en) 1860-11-06 Truss-bridge
US2976289A (en) 1961-03-21 X-tetrahydro -
US3254076A (en) 1966-05-31 Sulfamyl hydro
US2809194A (en) 1957-10-08 Thiadiazine type natriuretic agents
US2783241A (en) 1957-02-26 S-acylimino-x-substituted-az-i
US2882271A (en) 1959-04-14 Xcixcxh
US2937169A (en) 1960-05-17 Toiutf alrtqn of h
US115905A (en) 1871-06-13 Improvement in trunks
US3262852A (en) 1966-07-26 Vasodilator and anti-anginose com- pounds containing methoxy benzyl piperazines and method of using the same
US238A (en) 1837-06-15 Capstan
US2161938A (en) 1934-07-31 1939-06-13 Soc Of Chemical Ind Imidazolines
US2357985A (en) 1940-07-30 1944-09-12 Research Corp Synthesis of hexoestrol
DE905738C (de) 1943-06-11 1954-11-02 Diwag Chemische Fabriken Ag Verfahren zur Herstellung basischer Thymoldimethylaminoaethylaether
US2500444A (en) 1944-10-10 1950-03-14 Polaroid Corp Uramidohomomeroquinene
AT168063B (de) 1948-11-23 1951-04-10 Richter Gedeon Vegyeszet Verfahren zur Herstellung von neuen asymmetrischen Substitutionsprodukten des 2,4-Diamino-1,3,5-Triazins
DE860217C (de) 1950-10-28 1952-12-18 Albert Ag Chem Werke Verfahren zur Herstellung von 1-Hexyl-3, 7-dimethylxanthin
GB740932A (en) 1952-08-01 1955-11-23 Rhone Poulenc Sa Improvements in or relating to phenthiazine derivatives
US2661373A (en) 1953-03-02 1953-12-01 Kulz Ida Certain amino alcohols and ketones
US2816118A (en) 1953-11-12 1957-12-10 S B Penick & Company Inc Isolation of crystalline components from visnagan
FR1103113A (fr) 1954-04-15 1955-10-31 Triméthylol-alcanes et leur procédé de préparation
GB769757A (en) 1954-05-13 1957-03-13 American Cyanamid Co Improvements in or relating to the manufacture of sulfonamides
US2769015A (en) 1954-10-06 1956-10-30 Lab Laroche Navarron Process of preparing 3-methyl-chromone
GB795174A (en) 1954-10-13 1958-05-21 Upjohn Co Heterocyclic sulphonamides
GB807826A (en) 1955-03-14 1959-01-21 Thomae Gmbh Dr K Derivatives of pyrimido[5,4-d] pyrimidine and production thereof
FR1165845A (fr) 1955-05-28 1958-10-29 Philips Nv Amines secondaires portant des substituants et leur préparation
GB803372A (en) 1955-11-02 1958-10-22 Recordati Lab Farmacologico S Hydroxychromone derivatives and methods of preparing the same
US3012042A (en) 1956-12-21 1961-12-05 Belge Produits Chimiques Sa Benzofurans
NL224562A (https=) 1957-02-05
US2980679A (en) 1957-04-04 1961-04-18 Omikron Gagliardi Societa Di F Process for preparing heterocyclic sulfonamides
GB824547A (en) 1957-05-07 1959-12-02 Recordati Lab Farmacologico S Process for preparing flavone-7-ethyl oxyacetate
US3055904A (en) 1957-11-04 1962-09-25 Geigy Chem Corp New isoindoline derivatives
US2965655A (en) 1957-11-07 1960-12-20 Merck & Co Inc Process for preparing substituted 1-amino 2, 4-benzene-disulfonamides
US2965656A (en) 1957-11-07 1960-12-20 Merck & Co Inc Process for preparing substituted 1-amino-2, 4-benzene-disulfonamides
US2980699A (en) 1957-12-20 1961-04-18 S B Penick And Company Dihydropyranocoumarin derivatives and process for their production
FR1217929A (fr) 1958-03-03 1960-05-06 Ciba Geigy Procédé de préparation du 1,1-dioxyde de la 6-chloro-7-sulfamyl-3,4-dihydro-1,2,4-benzothiadiazine et de ses sels
CH366523A (de) 1958-04-14 1963-01-15 Eprova Ag Verfahren zur Herstellung der neuen 1,3,4,6- und 1,3,4,5-Tetranicotinoyl-fructose
NL238796A (https=) 1958-05-07
GB851287A (en) 1958-07-10 1960-10-12 British Drug Houses Ltd 5-chlorotoluene-2:4-disulphonamide and alkali metal salts thereof
DE1102750B (de) 1958-07-17 1961-03-23 Wuelfing J A Fa Verfahren zur Herstellung eines Salzes von Theophyllinbasen
GB856409A (en) 1958-07-26 1960-12-14 Chime Et Atomistique Improvements in and relating to a new pyridazine derivative and its process of preparation
GB862248A (en) 1958-08-04 1961-03-08 Italseber S P A Di-isopropylammonium salts of chloroacetic and chloropropionic acids
US2970082A (en) 1958-10-07 1961-01-31 Walker Lab Inc Aluminum nicotinate compositions for hypercholesteremia
GB885078A (en) 1959-01-12 1961-12-20 Ciba Ltd 3:4-dihydro-1:2:4-benzothiadiazine-1:1-dioxides and process for their manufacture
ES255386A1 (es) 1959-02-04 1960-09-16 Ciba Geigy Procedimiento para preparar derivados del 3,4-dihidro-1,2,4-benzotiadiazina-1,1,-diëxido
US3058882A (en) 1959-12-28 1962-10-16 Hoechst Ag N'-substituted-3-carboxy-6-halo-sulfanilamide and derivatives thereof
DE1102973B (de) 1960-03-25 1961-03-23 Bayer Ag Verfahren zur Herstellung von hoch gereinigten Kallikrein-Praeparaten
NL291944A (https=) 1960-05-04
DE1265758B (de) 1960-05-25 1968-04-11 Guidotti & C Spa Labor Verfahren zur Herstellung von o-(beta-Dialkylaminoaethoxy)-phenylketonen und deren Saeureadditionssalzen und quartaeren Salzen
US3081230A (en) 1960-09-08 1963-03-12 Smith Kline French Lab Diuretic and antihypertensive triaminoarylpteridines
DE1302648B (https=) 1960-09-27
SE300218B (https=) 1960-11-08 1968-04-22 Recip Ab
NL270803A (https=) 1960-11-09
US3255241A (en) 1961-01-19 1966-06-07 Merck & Co Inc (2-alkylidene acyl)phenoxy-and (2-alkylidene acyl)phenylmercaptocarboxylic acids
US3072653A (en) 1961-03-06 1963-01-08 Warner Lamber Pharmaceutical C 5-amino derivatives of 4-thiazolidinones and process therefor
DE1154810B (de) 1961-04-01 1963-09-26 Knoll Ag Verfahren zur Herstellung basisch substituierter Phenylacetonitrile
FR1312427A (fr) 1961-04-12 1962-12-21 Science Union Et Compagnie Soc Nouveaux dérivés de la pipérazine et leurs préparations
GB979994A (en) 1961-07-28 1965-01-06 May & Baker Ltd Isoindolinone derivatives
NL281593A (https=) 1961-07-31
US3160641A (en) 1961-08-07 1964-12-08 Atlas Chem Ind Purification of isosorbide
NL281975A (https=) 1961-08-12
GB984810A (en) 1961-10-05 1965-03-03 Farmaceutici Italia Polypeptides
DE1236523C2 (de) 1962-02-15 1975-06-12 Sanol-Arzneimittel Dr. Schwarz Gmbh, 4019 Monheim Verfahren zur herstellung von basischen phenylaethern und deren salzen
US3262977A (en) 1962-03-10 1966-07-26 Chinoin Gyogyszer Es Vegyeszet N-aralkyl-1, 1-diphenyl-propylamine derivatives
BE629910A (https=) 1962-03-22
US3188329A (en) 1962-04-10 1965-06-08 Colgate Palmolive Co Diuretic anils
US3228943A (en) 1962-06-11 1966-01-11 Lumilysergol derivatives
US3338899A (en) 1962-07-09 1967-08-29 Aron Samuel 3-phenyl-5-amino-1, 2, 4-oxadiazole compounds
US3265573A (en) 1962-07-27 1966-08-09 Squibb & Sons Inc Benzothiadiazinesulfonamide-1, 1-dioxide composition
BE639386A (https=) 1962-10-30
NL300886A (https=) 1962-11-23
NL301580A (https=) 1962-12-11
NL142872C (https=) 1963-03-28
FR1365504A (fr) 1963-05-24 1964-07-03 Soc Ind Fab Antibiotiques Sifa Nouveaux dérivés des thiachromanes et procédé de préparation
FR2790M (fr) 1963-05-24 1964-10-16 Soc Ind Fab Antibiotiques Sifa Nouveaux dérivés des thiachromanes.
GB1069343A (en) 1963-09-10 1967-05-17 Ici Ltd Propanolamine derivatives
US3238215A (en) 1963-10-17 1966-03-01 Sterling Drug Inc 1-[(3-, 2-, and 1-indolyl)-lower-alkyl-, lower-alkenyl-, and lower-alkynyl]piperidines
NL127996C (https=) 1963-11-19
BR6464291D0 (pt) 1963-11-26 1973-07-26 Merrell Inc Richardson Processo para preparar o novo composto quimico 1-1-di cloro-hexil-2-(2-piperidil)-etina
DE1278443C2 (de) 1963-11-30 1975-07-24 Bayer Ag, 5090 Leverkusen Verfahren zur herstellung von 2,4-disulfonamid-1-chlorbenzolen
NL128190C (https=) 1964-02-07
FR1390056A (fr) 1964-04-21 1965-02-19 Holding Ceresia S A Procédé de préparation de nouveaux dérivés du tétrahydronaphtalène et produits conformes à ceux obtenus par le présent procédé ou procédé similaire
NL127065C (https=) 1964-04-22
NL137318C (https=) 1964-06-09
US3422107A (en) 1964-09-05 1969-01-14 Albert Ag Chem Werke Certain oxoalkyldimethylxanthines and a process for the preparation thereof
NL130749C (https=) 1964-09-10
GB1078852A (en) 1964-09-30 1967-08-09 Ici Ltd Alkanolamine derivatives
NL6514807A (https=) 1964-11-18 1966-05-20
NL128191C (https=) 1965-01-12
US3929836A (en) 1965-05-11 1975-12-30 Hoffmann La Roche 2-(2-Lower alkylamino-1-hydroxy-ethyl)-substituted benzofurans
FR1460571A (fr) 1965-06-10 1966-03-04 Innothera Lab Sa Composés thiényl acétiques et leur préparation
DE1270544B (de) 1965-06-19 1968-06-20 Beiersdorf Ag 4-Chlor-5-sulfamylsalicylsaeure-(2', 6'-dimethyl)-anilid und dessen Alkali- oder Ammonium-Salze sowie Verfahren zu deren Herstellung
DE1545575C2 (de) 1965-12-16 1970-09-10 Asta-Werke Ag, Chemische Fabrik, 4812 Brackwede N, N'-Bis- eckige Klammer auf 3"(3', 4', 5'-trimethoxybenzoyloxy)-propyl eckige Klammer zu -homopiperazin
US3360518A (en) 1966-01-03 1967-12-26 Wallace & Tiernan Inc Tetrahydro-halo-sulfamyl quinazolinones
CH472404A (de) 1966-03-04 1969-05-15 Sandoz Ag Verfahren zur Herstellung neuer Indolderivate
CH469002A (de) 1966-06-21 1969-02-28 Sandoz Ag Verfahren zur Herstellung neuer Indolderivate
FR5733M (https=) 1966-09-27 1968-01-22
FR6087M (https=) 1967-01-10 1968-06-04
US3961071A (en) 1967-02-06 1976-06-01 Boehringer Ingelheim Gmbh Therapeutic compositions and method
US3940489A (en) 1967-02-06 1976-02-24 Boehringer Ingelheim Gmbh Therapeutic compositions and method
GB1160925A (en) 1967-02-08 1969-08-06 Menarini Sas 2-Substituted Benzofuran Derivatives
DE1668055B2 (de) 1967-03-10 1973-09-06 Farbwerke Hoechst AG, vormals Mei ster Lucius & Bruning, 6000 Frankfurt Basisch substituierte cyclopentylphenolaether, deren salze mit physiologisch vertraeglichen saeuren und verfahren zu deren herstellung
DE1670827C3 (de) 1967-03-20 1974-10-24 Bayer Ag, 5090 Leverkusen 4-(2'-Nitrophenyl)-2,6-dimethyl-3,5-dicarbmethoxy-1,4-dihydropyridin
US3563997A (en) 1967-12-04 1971-02-16 Yoshitomi Pharmaceutical Certain thieno(2,3-c)pyridines
US3511836A (en) 1967-12-13 1970-05-12 Pfizer & Co C 2,4,6,7-tetra substituted quinazolines
US3857952A (en) 1967-12-22 1974-12-31 May & Baker Ltd Certain benzene derivatives useful in treating cardiac disorders
NL6903138A (https=) 1968-03-02 1969-09-04
GB1203691A (en) 1968-03-06 1970-09-03 Science Union & Cie New disubstituted n-amino indoline derivatives and process for preparing them
GB1218591A (en) 1968-04-03 1971-01-06 Delalande Sa Derivatives of n-(3,4,5-trimethoxy cennamoyl) piperazine and their process of preparation
US4045482A (en) 1968-11-12 1977-08-30 Yamanouchi Pharmaceutical Co. Ltd. 4-(3-Isopropylamino-2-hydroxypropoxy indene
DE1815922C3 (de) 1968-12-20 1979-04-26 Boehringer Mannheim Gmbh, 6800 Mannheim 5-Phenyltetrazol-Derivate
FR8120M (https=) 1968-12-26 1970-08-03
GB1285038A (en) 1969-02-21 1972-08-09 Ici Ltd Alkanolamine derivatives
US3836671A (en) 1969-02-21 1974-09-17 Ici Ltd Alkanolamine derivatives for producing beta-adrenergic blockade
US3655663A (en) 1969-04-21 1972-04-11 Burton K Wasson 4-(3-secondary amino-2-hydroxy-proxy) 1 2 5-thiadiazoles
US3663570A (en) 1969-04-28 1972-05-16 Sankyo Co Coumarin derivatives
GB1262785A (en) 1969-04-29 1972-02-09 Orsymonde Improvements in or relating to phloroglucinol derivatives
CA956632A (en) 1969-05-16 1974-10-22 Yoshitomi Pharmaceutical Industries Phenoxy-aminopropanol derivatives
US4012444A (en) 1969-07-08 1977-03-15 Allen & Hanburys Limited 5-[1-Hydroxy-2-(1-methyl-3-phenylpropyl)aminoethyl] salicylamide and physiologically acceptable acid addition salts thereof
US3634583A (en) 1969-07-24 1972-01-11 Leo Pharm Prod Ltd Pharmaceutical composition for the treatment of oedematous conditions and hypertension
BE757001A (fr) 1969-10-10 1971-03-16 Cerpha Derives heterocycliques d'acides phenoxy acetique et leur preparation
US4018824A (en) 1969-11-28 1977-04-19 Teikoku Hormone Mfg. Co., Ltd. 1-Aryloxy-3-aminopropane derivatives
US3935259A (en) 1970-01-08 1976-01-27 Ciba-Geigy Corporation New amines and processes for their manufacture
US4038313A (en) 1970-01-08 1977-07-26 Ciba-Geigy Corporation Cycloalkylureido phenoxy propanolamines
SE354851B (https=) 1970-02-18 1973-03-26 Haessle Ab
US3770724A (en) 1970-03-31 1973-11-06 Roussel Uclaf Process for preparing pentacyclic alkaloids
GB1308191A (en) 1970-04-06 1973-02-21 Science Union & Cie Thiochroman derivatives and a process for preparing them
US3663597A (en) 1970-05-05 1972-05-16 American Home Prod Process for the purification of cyclandelate
FR2092133B1 (https=) 1970-05-06 1974-03-22 Orsymonde
US3669968A (en) 1970-05-21 1972-06-13 Pfizer Trialkoxy quinazolines
US4059622A (en) 1970-05-27 1977-11-22 Imperial Chemical Industries Limited Alkanolamine derivatives
FR2092895B1 (https=) 1970-06-29 1973-07-13 Lafon Victor
DE2117571C3 (de) 1971-04-10 1979-10-11 Bayer Ag, 5090 Leverkusen Unsymmetrische 1,4-Dihydropyridin-33-dicarbonsäureester, Verfahren zu ihrer Herstellung sowie ihre Verwendung als Arzneimittel
CA989411A (en) 1971-05-13 1976-05-18 Kakenyaku Kako Co. Benzofuran derivatives and preparation thereof
DE2815926A1 (de) 1978-04-13 1979-10-18 Boehringer Mannheim Gmbh Neue carbazolyl-(4)-oxy-propanolamin-derivate, verfahren zu ihrer herstellung und diese verbindungen enthaltende arzneimittel
US3773939A (en) 1971-11-24 1973-11-20 Janssen Pharmaceutica Nv N-arallyl-n'-aralkyl piperazine pharmaceutical compositions
JPS5229318B2 (https=) 1972-03-30 1977-08-01
US3910924A (en) 1972-04-13 1975-10-07 Otsuka Pharma Co Ltd 3,4-Dihydrocarbostyril derivatives and a process for preparing the same
ZA732937B (en) 1972-05-05 1974-03-27 Maggioni & C Spa Non mercurial diuretics
GB1435139A (en) 1972-08-17 1976-05-12 Sumitomo Chemical Co Thiazole derivatives
US3985758A (en) 1973-02-20 1976-10-12 Yamanouchi Pharmaceutical Co., Ltd. 1,4-Dihydropyridine derivatives
GB1390748A (en) 1973-04-09 1975-04-16 Continental Pharma Alkyl and cycloalkylthiophenylalkylaminoalkanols their salts and the preparation thereof
DE2319278C2 (de) 1973-04-17 1986-02-20 Bayer Ag, 5090 Leverkusen Pharmazeutisches Mittel
US3857981A (en) 1973-06-20 1974-12-31 Armour & Co Preserving red color in red meats
US4062950A (en) 1973-09-22 1977-12-13 Bayer Aktiengesellschaft Amino sugar derivatives
US4146643A (en) 1973-12-18 1979-03-27 Sandoz Ltd. Increasing vigilance or treating cerebral insufficiency with substituted vincamines
AT334385B (de) 1973-12-20 1976-01-10 Chemie Linz Ag Verfahren zur herstellung von neuen phenoxypropylaminderivaten und deren salzen
NL175059C (nl) 1974-02-23 Boehringer Mannheim Gmbh Bereiding van bloeddrukverlagende stoffen en van preparaten die ze bevatten.
GB1501632A (en) 1974-06-28 1978-02-22 Cm Ind Aromatic ketones having cardiovascular activity
GB1477664A (en) 1974-04-17 1977-06-22 Christiaens Sa A Pyridine derivatives
DE2419970C3 (de) 1974-04-25 1980-06-12 Hoechst Ag, 6000 Frankfurt 3-<l-Pyrrolidinyl)-4-phenoxy-5sulfamoylbenzoesäure und Verfahren zu ihrer Herstellung
DE2521113A1 (de) 1974-05-15 1976-03-18 Maggioni & C Spa Cycloaliphatische derivate von 3.3-diphenylpropylamin
JPS5612114B2 (https=) 1974-06-07 1981-03-18
US4338322A (en) 1975-07-02 1982-07-06 Fujisawa Pharmaceutical Co., Ltd. 1,4-Dihydropyridine derivatives, pharmaceutical compositions containing same and methods of effecting vasodilation using same
US4129565A (en) 1975-07-11 1978-12-12 Nisshin Flour Milling Co., Ltd. Isocarbostyril derivatives
US4340541A (en) 1975-08-15 1982-07-20 Sandoz Ltd. 4-(2-Benzoyloxy-3-tert.-butylaminopropoxy-2-methyl indole
US4035750A (en) 1975-10-14 1977-07-12 Eastman Kodak Company Electrophotographic apparatus having improved photoconductor regenerative structure and procedure
US4105776A (en) 1976-06-21 1978-08-08 E. R. Squibb & Sons, Inc. Proline derivatives and related compounds
US4154839A (en) 1975-11-05 1979-05-15 Bayer Aktiengesellschaft 2,6-Dimethyl-3-carboxymethoxy-4-(2-nitrophenyl)-5-carbisobutoxy-1,4-dihydropyridine
FR2330383A1 (fr) 1975-11-06 1977-06-03 Synthelabo Nouveaux ethers de phenols substitues, leurs sels, leur preparation et les medicaments qui les renferment
US4046889A (en) 1976-02-13 1977-09-06 E. R. Squibb & Sons, Inc. Azetidine-2-carboxylic acid derivatives
GB1544872A (en) 1976-06-25 1979-04-25 Sterling Drug Inc 4-hydroxyphenylalkanolamine derivatives and preparation thereof
DE2645710C2 (de) 1976-10-09 1985-06-27 Merck Patent Gmbh, 6100 Darmstadt Phenoxy-amino-propanole, Verfahren zu ihrer Herstellung und pharmazeutische Zubereitung
JPS608117B2 (ja) 1977-02-08 1985-02-28 財団法人微生物化学研究会 新生理活性物質エステラスチンおよびその製造法
DE2719912C3 (de) 1977-05-04 1979-12-06 Bayer Ag, 5090 Leverkusen Verfahren zur Isolierung von 0- |4,6-Dideoxy-4- [JJl S-O,4,6/5)-4,5,6-trihydroxy-3-hydroxymethyl-2cyclohexen-1-yl] -amino] - a -D-glucopyranosyl} -(I Pfeil nach rechts 4)-0- a D-glucopyranosyl-(l Pfeil nach rechts 4)-D-glucopyranose aus Kulturbrühen
US4466972A (en) 1977-06-20 1984-08-21 Sandoz Ltd. Benzoxadiazoles and benzothiadiazoles, their preparation and pharmaceutical compositions containing them
DE2733747C2 (de) 1977-07-27 1979-09-27 Hoechst Ag, 6000 Frankfurt Verfahren zur Herstellung von 2,2 Dichlorhydrazobenzol
NO154918C (no) 1977-08-27 1987-01-14 Bayer Ag Analogifremgangsmaate til fremstilling av terapeutisk aktive derivater av 3,4,5-trihydroksypiperidin.
CA1147342A (en) 1977-10-12 1983-05-31 Kazuo Imai Process of producing novel phenylethanolamine derivatives
US4188390A (en) 1977-11-05 1980-02-12 Pfizer Inc. Antihypertensive 4-amino-2-[4-(1,4-benzodioxan-2-carbonyl) piperazin-1-yl or homopiperazin-1-yl]quinazolines
IT1088554B (it) 1977-11-17 1985-06-10 F I D I A Spa Procedimento sellettivo per la preparazione di derivati della 7-indrossi cumarina
JPS5953920B2 (ja) 1977-12-28 1984-12-27 東洋醸造株式会社 新規なアミノ糖化合物およびその製法
JPS55301A (en) 1978-02-14 1980-01-05 Yamanouchi Pharmaceut Co Ltd 1,4-dihydropyridine-3,5-dicarboxylic ester derivative and its preparation
CA1121290A (en) 1978-02-14 1982-04-06 Yasuji Suhara Amino sugar derivatives
IT1094076B (it) 1978-04-18 1985-07-26 Acraf Cicloalchiltriazoli
US4172896A (en) 1978-06-05 1979-10-30 Dainippon Pharmaceutical Co., Ltd. Methane-sulfonamide derivatives, the preparation thereof and composition comprising the same
SE429652B (sv) 1978-06-30 1983-09-19 Haessle Ab 2.6-dimetyl-4-(2.3-diklorfenyl)-1.4-dihydropyridin-3.5-dikarboxylsyra-3-metylester-5-etylester
JPS559058A (en) 1978-07-06 1980-01-22 Dainippon Pharmaceut Co Ltd 1-(3-mercapto-2-methylpropanoyl)prolyl amino acid derivative
DE2845770A1 (de) 1978-10-19 1980-04-30 Schering Ag Neue prostacyclin-derivate und verfahren zu ihrer herstellung
IL58849A (en) 1978-12-11 1983-03-31 Merck & Co Inc Carboxyalkyl dipeptides and derivatives thereof,their preparation and pharmaceutical compositions containing them
US4231938A (en) 1979-06-15 1980-11-04 Merck & Co., Inc. Hypocholesteremic fermentation products and process of preparation
DE2928485A1 (de) 1979-07-14 1981-01-29 Bayer Ag Verwendung von harnstoffderivaten als arzneimittel bei der behandlung von fettstoffwechselstoerungen
US4508729A (en) 1979-12-07 1985-04-02 Adir Substituted iminodiacids, their preparation and pharmaceutical compositions containing them
US4444784A (en) 1980-08-05 1984-04-24 Merck & Co., Inc. Antihypercholesterolemic compounds
JPS56110665A (en) 1980-02-08 1981-09-01 Yamanouchi Pharmaceut Co Ltd Sulfamoyl-substituted phenetylamine derivative and its preparation
SE8004087L (sv) 1980-06-02 1981-12-03 Haessle Ab Nya parasubstituerade 3-fenoxi-1-alkylaminopropanol-2-er med betareceptorblockerande egenskaper, samt forfarande for deras framstellning, farmaceutiska beredningar innehallande desamma, och metod att behandla akut ...
DK149080C (da) 1980-06-06 1986-07-28 Sankyo Co Fremgangsmaade til fremstilling af derivater af ml-236b-carboxylsyre
US4394382A (en) 1980-06-17 1983-07-19 Kowa Company, Ltd. Dihydrobenzopyran compounds and pharmaceutical composition comprising said compounds
US4450171A (en) 1980-08-05 1984-05-22 Merck & Co., Inc. Antihypercholesterolemic compounds
US4344949A (en) 1980-10-03 1982-08-17 Warner-Lambert Company Substituted acyl derivatives of 1,2,3,4-tetrahydroisoquinoline-3-carboxylic acids
ES8207217A1 (es) 1980-10-09 1982-09-01 Hoechst Ag Procedimiento para la preparacion de un inactivador de alfa-amilasa
US4470972A (en) 1981-04-28 1984-09-11 Schering Corporation 7-Carboxyalkylaminoacyl-1,4-dithia-7-azaspiro[4.4]-nonane-8-carboxylic acids
ZA817261B (en) 1980-10-23 1982-09-29 Schering Corp Carboxyalkyl dipeptides,processes for their production and pharmaceutical compositions containing them
US4337201A (en) 1980-12-04 1982-06-29 E. R. Squibb & Sons, Inc. Phosphinylalkanoyl substituted prolines
FR2496699B1 (fr) 1980-12-22 1985-06-21 Siderurgie Fse Inst Rech Lance de soufflage de gaz oxydant, notamment d'oxygene, pour le traitement des metaux en fusion
EP0056194B1 (en) 1981-01-05 1984-09-12 Takeda Chemical Industries, Ltd. N-substituted pseudo-aminosugars, their production and use
US4452813A (en) 1981-05-22 1984-06-05 Taiho Pharmaceutical Company Limited Sulfonate derivatives, process for preparing same and antilipemic compositions containing the derivative
JPS57209270A (en) 1981-06-19 1982-12-22 Chugai Pharmaceut Co Ltd Proline derivative
US4410520A (en) 1981-11-09 1983-10-18 Ciba-Geigy Corporation 3-Amino-[1]-benzazepin-2-one-1-alkanoic acids
IE55867B1 (en) 1981-12-29 1991-02-14 Hoechst Ag New derivatives of bicyclic aminoacids,processes for their preparation,agents containing these compounds and their use,and new bicyclic aminoacids as intermediates and processes for their preparation
US4555502A (en) 1982-09-30 1985-11-26 Merck & Co., Inc. Aminoacyl-containing dipeptide derivatives useful as antihypertensives
DK161312C (da) 1982-03-11 1991-12-09 Pfizer Analogifremgangsmaade til fremstilling af 2-aminoalkoxymethyl-4-phenyl-6-methyl-1,4-dihydropyridin-3,5-dicarboxylsyreestere eller syreadditionssalte deraf samt phthalimidoderivater til anvendelse som udgangsmateriale ved fremgangsmaaden
US4448784A (en) 1982-04-12 1984-05-15 Hoechst-Roussel Pharmaceuticals, Inc. 1-(Aminoalkylphenyl and aminoalkylbenzyl)-indoles and indolines and analgesic method of use thereof
ATE50987T1 (de) 1982-05-10 1990-03-15 Takeda Chemical Industries Ltd Dihydropyridinderivate, deren herstellung und verwendung.
JPS6058233B2 (ja) 1982-05-24 1985-12-19 田辺製薬株式会社 ２−オキソイミダゾリジン誘導体及びその製法
US4452790A (en) 1982-06-23 1984-06-05 E. R. Squibb & Sons, Inc. Phosphonyl hydroxyacyl amino acid derivatives as antihypertensives
US4463176A (en) 1982-09-13 1984-07-31 Mead Johnson & Company Process for resolution of optical isomers
AU557175B2 (en) 1982-10-15 1986-12-11 Kyowa Hakko Kogyo Co. Ltd. 2,6-dimethyl-4-(3-nitro phenyl)-1,4-dihydro pyridine-3,5- dicarboxylic acid esters
US4739073A (en) 1983-11-04 1988-04-19 Sandoz Pharmaceuticals Corp. Intermediates in the synthesis of indole analogs of mevalonolactone and derivatives thereof
US4567175A (en) 1983-06-03 1986-01-28 Tanabe Seiyaku Co., Ltd. 8-Chloro-1,5-benzothiazepine derivatives
CA1247547A (en) 1983-06-22 1988-12-28 Paul Hadvary Leucine derivatives
US4678783B1 (en) 1983-11-04 1995-04-04 Asahi Chemical Ind Substituted isoquinolinesulfonyl compounds
US4654362A (en) 1983-12-05 1987-03-31 Janssen Pharmaceutica, N.V. Derivatives of 2,2'-iminobisethanol
FI844289L (fi) 1984-01-21 1985-07-22 Hoechst Ag Nya polypeptider med -amylashaemmande verkan, foerfarande foer deras framstaellning, deras anvaendning och farmaceutiska preparat.
GB8403866D0 (en) 1984-02-14 1984-03-21 Recordati Chem Pharm Diphenylalkylaminoalkyl esters
JPS60222472A (ja) 1984-03-30 1985-11-07 Kanebo Ltd 新規なピペラジン誘導体および該化合物を有効成分とする医薬組成物
US4699905A (en) 1984-04-10 1987-10-13 Sankyo Company, Limited Perhydrothiazepine derivatives, their preparation and their therapeutic use
US4672068A (en) 1984-05-04 1987-06-09 Fujirebio Kabushiki Kaisha Antihypertensive 1,4-dihydropyridines having a conjugated ester
NZ212895A (en) 1984-08-22 1988-07-28 Glaxo Spa 1,4-dihydropyridine derivatives and pharmaceutical compositions
US4634765A (en) 1984-12-18 1987-01-06 Merrell Dow Pharmaceuticals Inc. Homodisaccharide hypoglycemic agents
KR890004196B1 (ko) 1985-07-29 1989-10-27 산텐세이야꾸가부시끼가이샤 신규 벤조티아진 유도체의 제조방법
US4885284A (en) 1986-01-22 1989-12-05 Nissan Chemical Industries Ltd. Dihydropyridine-5-phosphonic acid cyclic propylene ester
US4847271A (en) 1986-01-27 1989-07-11 Merck & Co., Inc. Antihypercholesterolemic β-lactones
GB8608335D0 (en) 1986-04-04 1986-05-08 Pfizer Ltd Pharmaceutically acceptable salts
US5138069A (en) 1986-07-11 1992-08-11 E. I. Du Pont De Nemours And Company Angiotensin II receptor blocking imidazoles
CA1319144C (en) 1986-11-14 1993-06-15 Quirico Branca Tetrahydronaphthalene derivatives
US5041432A (en) 1987-01-30 1991-08-20 E. I. Du Pont De Nemours And Company Steroid derivatives useful as hypocholesterolemics
ATE61588T1 (de) 1987-08-03 1991-03-15 Delagrange Lab 1,4-dihydropyridine, verfahren zu ihrer herstellung und ihre verwendung als arzneimittel.
CA1336714C (en) 1987-08-20 1995-08-15 Yoshihiro Fujikawa Quinoline type mevalonolactone inhibitors of cholesterol biosynthesis
JP2569746B2 (ja) 1987-08-20 1997-01-08 日産化学工業株式会社 キノリン系メバロノラクトン類
US5192772A (en) 1987-12-09 1993-03-09 Nippon Shinyaku Co. Ltd. Therapeutic agents
US4804770A (en) 1988-04-29 1989-02-14 E. R. Squibb & Sons, Inc. Process for preparing a keto-phosphonate intermediate useful in preparing HMG-CoA reductase inhibitors
EP0344383A1 (en) 1988-06-02 1989-12-06 Merrell Dow Pharmaceuticals Inc. Novel alpha-Glucosidase inhibitors
JP2853227B2 (ja) 1988-10-13 1999-02-03 ノバルテイス・アクチエンゲゼルシヤフト ７置換‐ヘプト‐６‐エン酸、ヘプタン酸及び誘導体並びにそれらの中間体の製法
DE3836675A1 (de) 1988-10-28 1990-05-03 Hoechst Ag Glykosidase-inhibitor salbostatin, verfahren zu seiner herstellung und seine verwendung
WO1990005132A1 (fr) 1988-11-11 1990-05-17 Banyu Pharmaceutical Co., Ltd. Derives d'allylamine substitues, procede de preparation et utilisation
US5185351A (en) 1989-06-14 1993-02-09 Smithkline Beecham Corporation Imidazolyl-alkenoic acids useful as angiotensin II receptor antagonists
FI94339C (fi) 1989-07-21 1995-08-25 Warner Lambert Co Menetelmä farmaseuttisesti käyttökelpoisen /R-(R*,R*)/-2-(4-fluorifenyyli)- , -dihydroksi-5-(1-metyylietyyli)-3-fenyyli-4-/(fenyyliamino)karbonyyli/-1H-pyrroli-1-heptaanihapon ja sen farmaseuttisesti hyväksyttävien suolojen valmistamiseksi
US5064856A (en) 1989-07-31 1991-11-12 Merck & Co., Inc. Novel hmg-coa synthase inhibitors
US5391571A (en) 1989-11-15 1995-02-21 American Home Products Corporation Cholesterol ester hydrolase inhibitors
DE122007000050I1 (de) 1990-02-19 2007-11-08 Novartis Ag Acylverbindungen
US5270317A (en) 1990-03-20 1993-12-14 Elf Sanofi N-substituted heterocyclic derivatives, their preparation and the pharmaceutical compositions in which they are present
US5102915A (en) 1990-03-22 1992-04-07 Merrell Dow Pharmaceuticals Inc. Cyclopropyl squalene derivatives and their use as inhibitors of cholesterol synthesis
US5051534A (en) 1990-03-22 1991-09-24 Merrell Dow Pharmaceuticals Inc. Novel cyclopropyl squalene derivatives and their use as inhibitors of cholesterol synthesis
US5064864A (en) 1990-03-30 1991-11-12 Merrell Dow Pharmaceuticals Inc. Di- and tetra-fluoro analogs of squalene as inhibitors of squalene epoxidase
US5011859A (en) 1990-03-30 1991-04-30 Merrell Dow Pharmaceuticals Inc. Di- and tetra-fluoro analogs of squalene as inhibitors of squalene epoxidase
US5196444A (en) 1990-04-27 1993-03-23 Takeda Chemical Industries, Ltd. 1-(cyclohexyloxycarbonyloxy)ethyl 2-ethoxy-1-[[2'-(1H-tetrazol-5-yl)biphenyl-4-yl]methyl]benzimidazole-7-carboxylate and compositions and methods of pharmaceutical use thereof
US5504078A (en) 1990-06-08 1996-04-02 Merrell Dow Pharmaceuticals Inc. α-glucosidase inhibitors
US5120729A (en) 1990-06-20 1992-06-09 Merck & Co., Inc. Beta-lactams as antihypercholesterolemics
ZA915659B (en) 1990-07-25 1992-05-27 Merrell Dow Pharma Novel piperidyl ethers and thioethers as inhibitors of cholesterol biosynthesis
US5026554A (en) 1990-09-13 1991-06-25 Merck & Co., Inc. Method of inhibiting fungal growth using squalene synthetase inhibitors
US5177080A (en) 1990-12-14 1993-01-05 Bayer Aktiengesellschaft Substituted pyridyl-dihydroxy-heptenoic acid and its salts
US5084461A (en) 1991-03-27 1992-01-28 Merrell Dow Pharmaceuticals Inc. Azadecalin amides and thioamides as inhibitors of cholesterol biosynthesis
JP2648897B2 (ja) 1991-07-01 1997-09-03 塩野義製薬株式会社 ピリミジン誘導体
US5274143A (en) 1991-07-23 1993-12-28 Hoffmann-La Roche Inc. Process for the preparation of (R)-3-hexyl-5,6-dihydro-4-hydroxy-6-undecyl-2H-pyran-2-one and (R)-5,6-dihydro-6-undecyl-2H-pyran-2,4(3H)-dione
WO1993012069A1 (fr) 1991-12-16 1993-06-24 Yamanouchi Pharmaceutical Co., Ltd. Nouveau derive d'alcool amine ou son sel
WO1993011782A1 (en) 1991-12-19 1993-06-24 Southwest Foundation For Biomedical Research Cetp inhibitor polypeptide, antibodies against the synthetic polypeptide and prophylactic and therapeutic anti-atherosclerosis treatments
CA2098167C (en) 1992-06-24 2006-12-19 Dorothea Isler Foodstuffs and feedstuffs containing a lipase inhibitor
US5629295A (en) 1992-06-26 1997-05-13 Pfizer Inc. Steroidal glycosides for treating hypercholesterolemia
US5350758A (en) 1992-07-08 1994-09-27 Merrell Dow Pharmaceuticals Inc. Piperidyl sulfonamides and sulfoxamides as inhibitors of cholesterol biosynthesis
GB9217295D0 (en) 1992-08-14 1992-09-30 Wellcome Found Controlled released tablets
US5728704A (en) 1992-09-28 1998-03-17 Pfizer Inc. Substituted pyridmidines for control of diabetic complications
FR2697250B1 (fr) 1992-10-28 1995-01-20 Fournier Ind & Sante Dérivés de beta,beta-diméthyl-4-pipéridineéthanol et de 1,2,3,6-tétrahydro-beta,beta-diméthyl-4-pyridineéthanol, leur procédé de préparation et leur utilisation en thérapeutique.
FR2697252B1 (fr) 1992-10-28 1994-12-09 Fournier Ind & Sante Dérivés de 1,2,3,5,6,7,8,8a-octahydro-5,5,8a-triméthyl-(8abeta)-6-isoquinolineamine, leur procédé de préparation et leur utilisation en thérapeutique.
DE4309553A1 (de) 1993-03-24 1994-09-29 Bayer Ag Verfahren zur Herstellung von 3R,5S-(+)-Natrium-erythro-(E)-7-(4-(4-flurophenyl)-2,6-diisopropyl-5-methoxymethyl-pyrid-3-yl)-3,5-dihydroxy-hept-6-enoat
US5541231A (en) 1993-07-30 1996-07-30 Glaxo Wellcome Inc. Stabilized Pharmaceutical
US5358970A (en) 1993-08-12 1994-10-25 Burroughs Wellcome Co. Pharmaceutical composition containing bupropion hydrochloride and a stabilizer
GB9315856D0 (en) 1993-07-30 1993-09-15 Wellcome Found Stabilized pharmaceutical
TW381025B (en) 1993-08-05 2000-02-01 Hoffmann La Roche Pharmaceutical composition containing a glucosidase inhibitor and a lipase inhibitor
PT765313E (pt) 1994-06-17 2003-11-28 Hoffmann La Roche Derivados de n,n'-bis(quinolin-4-il)-diamina a sua preparacao e a sua utilizacao como agentes anti-malaria
KR970706242A (ko) 1994-10-04 1997-11-03 후지야마 아키라 우레아 유도체 및 ACAT-억제제로서 그의 용도(Urea derivatives and their use as ACAT-inhibitors)
JPH08143457A (ja) 1994-11-21 1996-06-04 Microbial Chem Res Found 酵素阻害剤および高脂血症抑制剤
WO1996018616A1 (en) 1994-12-12 1996-06-20 Merck & Co., Inc. Substituted 2-aminopyridines as inhibitors of nitric oxide synthase
US5510379A (en) 1994-12-19 1996-04-23 Warner-Lambert Company Sulfonate ACAT inhibitors
GB9504066D0 (en) 1995-03-01 1995-04-19 Pharmacia Spa Phosphate derivatives of ureas and thioureas
EP0738510A3 (fr) 1995-04-20 2005-12-21 L'oreal Utilisation d'un inhibiteur d'HMG-coenzyme A-reductase pour lutter contre le vieillissement de la peau et pour traiter l'acné. Composition comprenant au moins un inhibiteur HMG-coenzyme A reductase et au moins un actif possédant des propriétes desquamantes
DE69523182T2 (de) 1995-06-06 2002-02-07 Pfizer Substituierte n-(indol-2-carbonyl)-glycinamide und derivate als glycogen phosphorylase inhibitoren
FI974437A7 (fi) 1995-06-06 1997-12-05 Pfizer Substituoituja N-(indoli-2-karbonyyli)amideja ja johdannaisia glykogee nifosforylaasi-inhibiittoreina
WO1996040640A1 (en) 1995-06-07 1996-12-19 Pfizer Inc. BIPHENYL-2-CARBOXYLIC ACID-TETRAHYDRO-ISOQUINOLIN-6-YL AMIDE DERIVATIVES, THEIR PREPARATION AND THEIR USE AS INHIBITORS OF MICROSOMAL TRIGLYCERIDE TRANSFER PROTEIN AND/OR APOLIPOPROTEIN B (Apo B) SECRETION
NZ325248A (en) 1995-12-23 1999-09-29 Pfizer Res & Dev Quinoline and quinazoline compounds useful in therapy
JPH105585A (ja) 1996-06-27 1998-01-13 Toagosei Co Ltd リチウムイオン吸着剤
SE9603285D0 (sv) 1996-09-10 1996-09-10 Astra Ab New compounds
US5874438A (en) 1996-10-11 1999-02-23 Bayer Aktiengesellschaft 2,2'-bridged bis-2,4-diaminoquinazolines
EA001539B1 (ru) 1996-11-27 2001-04-23 Пфайзер Инк. Амиды, ингибирующие секрецию аполипопротеина в (аро в) и/или микросомного протеина переноса триглицеридов (мтр)
DE69839355T2 (de) 1997-07-29 2009-06-04 Alcon Laboratories, Inc., Fort Worth Ophthalmische Zusammensetzungen enthaltend Galaktomannanpolymere und Borat
AU2483599A (en) 1998-01-29 1999-08-16 Sepracor, Inc. Pharmaceutical uses of optically pure (-)-bupropion
US6197786B1 (en) 1998-09-17 2001-03-06 Pfizer Inc 4-Carboxyamino-2-substituted-1,2,3,4-tetrahydroquinolines
GT199900147A (es) 1998-09-17 1999-09-06 1, 2, 3, 4- tetrahidroquinolinas 2-sustituidas 4-amino sustituidas.
US8889112B2 (en) 1999-09-16 2014-11-18 Ocularis Pharma, Llc Ophthalmic formulations including selective alpha 1 antagonists
US6683113B2 (en) 1999-09-23 2004-01-27 Pharmacia Corporation (R)-chiral halogenated substituted N,N-Bis-benzyl aminioalcohol compounds useful for inhibiting cholesteryl ester transfer protein activity
US20040138284A1 (en) 2000-02-11 2004-07-15 Matthias Wiesner Indol-3-yl derivatives
GB0014022D0 (en) 2000-06-08 2000-08-02 Novartis Ag Organic compounds
WO2002020500A2 (en) 2000-09-01 2002-03-14 Icos Corporation Materials and methods to potentiate cancer treatment
EP1217000A1 (en) 2000-12-23 2002-06-26 Aventis Pharma Deutschland GmbH Inhibitors of factor Xa and factor VIIa
BR0207285A (pt) 2001-02-15 2004-02-10 Pfizer Producs Inc Agonistas de ppar
JP2004520397A (ja) 2001-02-15 2004-07-08 ファイザー・プロダクツ・インク 増殖性アクチベータ受容体（ｐｐａｒ）化合物
EP1491541B1 (en) 2001-03-30 2007-01-24 Pfizer Products Inc. Pyridazinone aldose reductase inhibitors
CZ20033309A3 (cs) 2001-06-07 2004-05-12 Eliálillyáandácompany Modulátory receptorů aktivovaných peroxizomálními proliferátory }PPARB
CN104744461A (zh) 2001-09-21 2015-07-01 百时美施贵宝公司 含有内酰胺的化合物及其衍生物作为Xa因子的抑制剂
AU2003209321A1 (en) 2002-01-18 2003-07-30 Pharmacia Corporation Substituted pyridazinones as inhibitors of p38
US6875780B2 (en) 2002-04-05 2005-04-05 Warner-Lambert Company Compounds that modulate PPAR activity and methods for their preparation
EP1505966A4 (en) 2002-05-10 2006-08-30 Bristol Myers Squibb Co 1,1-DISUBSTITUTED CYCLOALKYL DERIVATIVES AS FACTOR XA HEMMER
EP1542948A4 (en) 2002-08-23 2008-12-17 Univ Connecticut NEW BIPHENYL AND BIPHENYLENE CANNABINOIDS
AU2003286711A1 (en) 2002-10-25 2004-05-13 Vertex Pharmaceuticals Incorporated Indazolinone compositions useful as kinase inhibitors
EP1578715B1 (en) * 2002-12-20 2011-03-02 Bayer Pharmaceuticals Corporation Indane acetic acid derivatives and their use as pharmaceutical agents, intermediates, and method of preparation
US20050197350A1 (en) 2003-03-31 2005-09-08 Taisho Pharmaceutical Co., Ltd. Novel quinoline, tetrahydroquinazoline, and pyrimidine derivatives and methods of treatment related to the use thereof
TW200503747A (en) 2003-04-22 2005-02-01 Avanir Pharmaceuticals Peptide mediators of reverse cholesterol transport for the treatment of hypercholesterolemia
US6933289B2 (en) 2003-07-01 2005-08-23 Allergan, Inc. Inhibition of irritating side effects associated with use of a topical ophthalmic medication
EP1654002B2 (en) 2003-08-07 2014-01-29 Allergan, Inc. Compositions for delivery of therapeutics into the eyes
US20050059744A1 (en) 2003-09-12 2005-03-17 Allergan, Inc. Methods and compositions for the treatment of pain and other alpha 2 adrenergic-mediated conditions
BRPI0515500A (pt) 2004-09-20 2008-07-29 Xenon Pharmaceuticals Inc derivados piridazina para inibição de estearoil-coa-desaturase
WO2006035967A1 (en) 2004-09-30 2006-04-06 Taisho Pharmaceutical Co., Ltd. Pyridine derivatives and their use as medicaments for treating diseases related to mch receptor
US7381732B2 (en) 2004-10-26 2008-06-03 Bristol-Myers Squibb Company Pyrazolobenzamides and derivatives as factor Xa inhibitors
WO2006051311A1 (en) 2004-11-12 2006-05-18 Galapagos Nv Nitrogen heteroaromatic compounds which bind to the active site of protein kinase enzymes
GB0428082D0 (en) 2004-12-22 2005-01-26 Welcome Trust The Ltd Therapeutic compounds
EP1853573A1 (en) * 2005-02-25 2007-11-14 Rigel Pharmaceuticals, Inc. Benzisothiazoles useful for treating or preventing hcv infection
WO2006126081A2 (en) 2005-05-24 2006-11-30 Pharmacia & Upjohn Company Llc Pyridino [2 , 3-b] pyrazinones as pde-5 inhibitors
NZ564222A (en) 2005-06-14 2011-10-28 Taigen Biotechnology Co Ltd Pyrimidine compounds
US20070203236A1 (en) 2006-01-11 2007-08-30 Smith Jeffrey W Novel antagonists of the human fatty acid synthase thioesterase
JP2007291087A (ja) 2006-03-29 2007-11-08 Taisho Pharmaceut Co Ltd ピリジン誘導体及びその使用に関連する治療法
HRP20130044T1 (hr) 2006-07-25 2013-02-28 Cephalon, Inc. Derivati piridizinona
WO2008046216A1 (en) 2006-10-18 2008-04-24 Methylgene, Inc. Kinase inhibitors and uses thereof
EP2121619A2 (en) 2006-11-24 2009-11-25 AC Immune S.A. Compounds for the treatment of diseases associated with amyloid or amyloid-like proteins
KR101442288B1 (ko) 2006-12-13 2014-09-19 지보당 네덜란드 서비시즈 비.브이. 카복실산과 퓨린, 피리미딘, 뉴클레오사이드 또는 뉴클레오타이드의 향미 조절 유도체
US7803809B2 (en) 2008-11-12 2010-09-28 Amgen Inc. Substituted pyrano [2,3-b] pyridinamine compounds as beta-secretase modulators and methods of use
CN102099036B (zh) 2008-06-03 2015-05-27 英特芒尼公司 用于治疗炎性疾患和纤维化疾患的化合物和方法
WO2010048149A2 (en) 2008-10-20 2010-04-29 Kalypsys, Inc. Heterocyclic modulators of gpr119 for treatment of disease
SG175390A1 (en) 2009-04-29 2011-12-29 Amarin Corp Plc Pharmaceutical compositions comprising epa and a cardiovascular agent and methods of using the same
US20110009628A1 (en) 2009-07-08 2011-01-13 Haiyan Liu Compounds and Compositions for Modulating Lipid Levels and Methods of Preparing Same
WO2011008931A2 (en) 2009-07-15 2011-01-20 Cystic Fibrosis Foundation Therapeutics, Inc. Arylpyrimidine compounds and combination therapy comprising same for treating cystic fibrosis & related disorders
SG178106A1 (en) 2009-08-05 2012-03-29 Versitech Ltd Antiviral compounds and methods of making and using thereof
US20120219558A1 (en) 2009-09-25 2012-08-30 Yan Ni Antagonists of pcsk9
CN102596249A (zh) 2009-10-30 2012-07-18 默沙东公司 Ax1和ax189 pcsk9拮抗剂和变体
IN2012DN03824A (https=) 2009-10-30 2015-08-28 Merck Sharp & Dohme
AR079336A1 (es) 2009-12-11 2012-01-18 Irm Llc Antagonistas de la pro-proteina convertasa-subtilisina/quexina tipo 9 (pcsk9)
EP2558491B1 (en) 2010-04-13 2018-07-04 Bristol-Myers Squibb Company Fibronectin based scaffold domain proteins that bind pcsk9
AU2011253058A1 (en) 2010-05-13 2012-12-06 Amgen Inc. Heteroaryloxycarbocyclyl compounds as PDE10 inhibitors
WO2011147199A1 (en) 2010-05-28 2011-12-01 Versitech Limited Compounds and methods for treating viral infections
US8450316B2 (en) 2010-06-24 2013-05-28 Trustees Of Tufts College Niacin mimetics, and methods of use thereof
WO2011163612A1 (en) 2010-06-24 2011-12-29 Trustees Of Tufts College Niacin mimetics, and methods of use thereof
US9050334B2 (en) 2010-07-16 2015-06-09 Innov88 Llc MIF inhibitors and their uses
WO2012016133A2 (en) 2010-07-29 2012-02-02 President And Fellows Of Harvard College Ros1 kinase inhibitors for the treatment of glioblastoma and other p53-deficient cancers
WO2012054438A1 (en) 2010-10-22 2012-04-26 Schering Corporation Anti-pcsk9
US8987271B2 (en) 2010-12-22 2015-03-24 Eutropics Pharmaceuticals, Inc. 2,2′-biphenazine compounds and methods useful for treating disease
CN103261230A (zh) 2010-12-22 2013-08-21 霍夫曼-拉罗奇有限公司 抗pcsk9抗体及使用方法
SG192117A1 (en) 2011-01-28 2013-08-30 Sanofi Sa Human antibodies to pcsk9 for use in methods of treating particular groups of subjects
CN103339110A (zh) 2011-01-28 2013-10-02 诺瓦提斯公司 作为cdk9抑制剂的取代的杂-联芳基化合物及其用途
WO2012109530A1 (en) 2011-02-11 2012-08-16 Irm Llc Pcsk9 antagonists
WO2012142498A2 (en) 2011-04-13 2012-10-18 Innovimmune Biotherapeutics, Inc. Mif inhibitors and their uses
JOP20200043A1 (ar) 2011-05-10 2017-06-16 Amgen Inc طرق معالجة أو منع الاضطرابات المختصة بالكوليسترول
WO2012162635A1 (en) 2011-05-26 2012-11-29 Sunovion Pharmaceuticals Inc. Metabotropic glutamate receptors 5 modulators and methods of use thereof
WO2012170607A2 (en) 2011-06-10 2012-12-13 Novartis Ag Use of pcsk9 antagonists
WO2012168491A1 (en) 2011-06-10 2012-12-13 Novartis Ag Pharmaceutical formulations of pcsk9 antagonists
WO2012177741A1 (en) 2011-06-20 2012-12-27 Genentech, Inc. Pcsk9-binding polypeptides and methods of use
BR112014000392A2 (pt) 2011-07-14 2017-02-21 Pfizer tratamento com anticorpos anti-pcsk9
US8815909B2 (en) 2011-07-18 2014-08-26 Bristol-Myers Squibb Company Diaminocyclohexane compounds and uses thereof
AR087305A1 (es) 2011-07-28 2014-03-12 Regeneron Pharma Formulaciones estabilizadas que contienen anticuerpos anti-pcsk9, metodo de preparacion y kit
JP5741850B2 (ja) 2011-09-13 2015-07-01 コニカミノルタ株式会社 光学フィルム、それを含む偏光板および液晶表示装置
AR087715A1 (es) 2011-09-16 2014-04-09 Lilly Co Eli Anticuerpos anti pcsk9 y usos de los mismos
HUE069234T2 (hu) 2011-09-16 2025-02-28 Regeneron Pharma Eljárások lipoprotein(a)-szint csökkentésére proprotein-konvertáz szubtilizin/kexin 9 (PCSK9) inhibitorának beadásával
US9879093B2 (en) 2011-12-20 2018-01-30 Adaerata, Limited Partnershp Single domain antibodies as inhibitors of PCSK9
MX367352B (es) 2012-01-06 2019-08-16 Gemphire Therapeutics Inc Metodos para reducir el riesgo de padecer una enfermedad cardiovascular.
TW201348231A (zh) * 2012-02-29 2013-12-01 Amgen Inc 雜雙環化合物
PT2822936T (pt) * 2012-03-07 2021-12-02 Univ Of Delhi Derivados da aminoquinolina e suas utilizações
JPWO2013137371A1 (ja) * 2012-03-15 2015-08-03 興和株式会社 新規ピリミジン化合物及びそれらを含有する医薬
WO2013148284A1 (en) 2012-03-29 2013-10-03 Genentech, Inc. Antibodies that bind to a pcsk9 cleavage site and methods of use
EP2844733B1 (en) 2012-04-18 2020-07-15 Hemoshear, LLC In vitro model for pathological or physiologic conditions
EA039663B1 (ru) 2012-05-03 2022-02-24 Амген Инк. Применение антитела против pcsk9 для снижения сывороточного холестерина лпнп и лечения связанных с холестерином расстройств
US9255154B2 (en) 2012-05-08 2016-02-09 Alderbio Holdings, Llc Anti-PCSK9 antibodies and use thereof
KR20150059638A (ko) 2012-05-25 2015-06-01 카타베이시스 파마슈티칼즈, 인코포레이티드 전구단백질 전환효소 섭틸리신/켁신 9형 저하 방법
EP2861624A1 (en) 2012-06-15 2015-04-22 F. Hoffmann-La Roche AG Anti-pcsk9 antibodies, formulations, dosing, and methods of use
CA2877766A1 (en) 2012-07-03 2014-01-09 Majambu Mbikay Quercetin-3-glucoside and uses thereof
BR112014030284B1 (pt) 2012-07-18 2021-11-30 Sunshine Lake Pharma Co., Ltd Composto, composição farmacêutica, e, uso de um composto ou de uma composição farmacêutica
US9540449B2 (en) 2012-08-13 2017-01-10 Regeneron Pharmaceuticals, Inc. Anti-PCSK9 antibodies with pH-dependent binding characteristics
UA116217C2 (uk) 2012-10-09 2018-02-26 Санофі Пептидна сполука як подвійний агоніст рецепторів glp1-1 та глюкагону
AR092924A1 (es) 2012-10-09 2015-05-06 Sanofi Sa Derivados de pirrolidinona como moduladores de gpr119 para el tratamiento de diabetes, obesidad, dislipidemia y trastornos relacionados
AU2013366692B2 (en) 2012-12-21 2017-11-23 Sanofi Dual GLP1/GIP or trigonal GLP1/GIP/Glucagon agonists
WO2014107739A1 (en) 2013-01-07 2014-07-10 Eleven Biotherapeutics, Inc. Antibodies against pcsk9
TWI644899B (zh) 2013-02-04 2018-12-21 健生藥品公司 Ｆｌａｐ調節劑
EP2951157A1 (en) 2013-02-04 2015-12-09 Merck Patent GmbH Positive allosteric modulators of mglur3
WO2014127316A2 (en) 2013-02-15 2014-08-21 Srx Cardio, Llc Proprotein convertase subtilisin/kexin type 9 (pcsk9) allosteric binding ligands to mudulate serum low density lipoprotein (ldl) levels
ME03336B (me) * 2013-03-12 2019-10-20 Vertex Pharma Inhibitori dnk-pk
HK1213194A1 (zh) 2013-03-14 2016-06-30 Daiichi Sankyo Co., Ltd. 用於新型的结合蛋白质pcsk9
WO2014150983A2 (en) 2013-03-15 2014-09-25 Amgen Inc. Human antigen binding proteins that bind to proprotein convertase subtilisin kexin type 9
EP2968985A2 (en) 2013-03-15 2016-01-20 Amgen, Inc. Human antigen binding proteins that bind to proprotein convertase subtilisin kexin type 9
EP2968266B1 (en) 2013-03-15 2019-05-01 Shifa Biomedical Corporation Anti-proprotein convertase subtilisin kexin type 9 (anti-pcsk9) compounds in the treatment and/or prevention of cardiovascular diseases
EP2961765A4 (en) 2013-03-15 2016-11-09 Adaerata Ltd Partnership SMALL MOLECULAR PCSK9 MODULATORS AND METHOD OF USE THEREOF
CN105473141A (zh) 2013-03-15 2016-04-06 实发生物医学公司 治疗和/或预防心血管疾病的抗pcsk9化合物和方法
EP2986599A1 (en) 2013-04-17 2016-02-24 Pfizer Inc. N-piperidin-3-ylbenzamide derivatives for treating cardiovascular diseases
TWI682780B (zh) 2013-05-30 2020-01-21 美商再生元醫藥公司 醫藥組成物用於製造治療與ｐｃｓｋ９功能獲得性突變有關之體染色體顯性高膽固醇血症的藥物之用途
US10111953B2 (en) 2013-05-30 2018-10-30 Regeneron Pharmaceuticals, Inc. Methods for reducing remnant cholesterol and other lipoprotein fractions by administering an inhibitor of proprotein convertase subtilisin kexin-9 (PCSK9)
US10494442B2 (en) 2013-06-07 2019-12-03 Sanofi Biotechnology Methods for inhibiting atherosclerosis by administering an inhibitor of PCSK9
US9776995B2 (en) 2013-06-12 2017-10-03 Amgen Inc. Bicyclic sulfonamide compounds as sodium channel inhibitors
CA2916259C (en) 2013-06-28 2024-02-20 Amgen Inc. Methods for treating homozygous familial hypercholesterolemia
AR092240A1 (es) 2013-08-26 2015-04-08 Sunshine Lake Pharma Co Ltd Derivados heterociclicos nitrogenados y su aplicacion en farmacos
CN105658232A (zh) 2013-08-30 2016-06-08 阿尔莫生物科技股份有限公司 使用白细胞介素-10治疗疾病和病症的方法
ES2914978T3 (es) 2013-10-11 2022-06-20 Sanofi Biotechnology Uso de un inhibidor de PCSK9 para tratar hiperlipidemia
CN104558685B (zh) 2013-10-24 2017-09-29 中国石油化工股份有限公司 一种磷氮膨胀型阻燃剂及其合成方法
JP2017019724A (ja) 2013-10-25 2017-01-26 第一三共株式会社 置換ピリジン化合物および他の医薬の組み合わせ
CN118105480A (zh) 2013-11-12 2024-05-31 赛诺菲生物技术公司 用于与pcsk9抑制剂一起使用的给药方案
HK1224186A1 (zh) 2013-11-20 2017-08-18 Cymabay Therapeutics, Inc. 纯阖家族型高胆固醇血症的治疗
EP3080148A2 (en) 2013-12-11 2016-10-19 Glycotope GmbH Glycosylated glycophorin peptides
EP3080152A1 (en) 2013-12-13 2016-10-19 Sanofi Non-acylated exendin-4 peptide analogues
TW201609798A (zh) 2013-12-13 2016-03-16 賽諾菲公司 Ｅｘｅｎｄｉｎ－４胜肽類似物
WO2015086733A1 (en) 2013-12-13 2015-06-18 Sanofi Dual glp-1/glucagon receptor agonists
WO2015086728A1 (en) 2013-12-13 2015-06-18 Sanofi Exendin-4 peptide analogues as dual glp-1/gip receptor agonists
TW201609800A (zh) 2013-12-13 2016-03-16 賽諾菲公司 做為雙重ｇｌｐ－１／升糖素受體促效劑之艾塞那肽－４胜肽類似物
EP3080154B1 (en) 2013-12-13 2018-02-07 Sanofi Dual glp-1/gip receptor agonists
EA201691320A1 (ru) 2014-02-14 2016-11-30 Ридженерон Фармасьютикалз, Инк. Способы лечения пациентов с гиперхолестеринемией, которая устойчива к терапии умеренными дозами статинов
WO2015140079A1 (en) 2014-03-17 2015-09-24 Sanofi Methods for treating subjects with primary hypercholesterolemia that is not adequately controlled
LT3119757T (lt) 2014-03-17 2018-07-10 Pfizer Inc. Diacilglicerolio aciltransferazės 2 inhibitoriai, skirti panaudoti metabolinių ir susijusių ligų gydyme
AR099937A1 (es) 2014-04-04 2016-08-31 Sanofi Sa Compuestos de isoindolinona como moduladores de gpr119 para el tratamiento de diabetes, obesidad, dislipidemia y trastornos relacionados
JP2017515797A (ja) 2014-04-04 2017-06-15 サノフイ 糖尿病、肥満、脂質異常症および関連障害の治療のためのｇｐｒ１１９モジュレーターとしての置換インダノン化合物
TW201625605A (zh) 2014-04-04 2016-07-16 賽諾菲公司 用於治療糖尿病、肥胖、血脂異常及相關病症之作為ｇｐｒ１１９調節劑的經取代之稠合雜環類
TW201625670A (zh) 2014-04-07 2016-07-16 賽諾菲公司 衍生自ｅｘｅｎｄｉｎ－４之雙重ｇｌｐ－１／升糖素受體促效劑
TW201625668A (zh) 2014-04-07 2016-07-16 賽諾菲公司 作為胜肽性雙重ｇｌｐ－１／昇糖素受體激動劑之艾塞那肽－４衍生物
TW201625669A (zh) 2014-04-07 2016-07-16 賽諾菲公司 衍生自艾塞那肽－４（Ｅｘｅｎｄｉｎ－４）之肽類雙重ＧＬＰ－１／升糖素受體促效劑
US20170183306A1 (en) 2014-05-30 2017-06-29 Universite Paris Decartes Cyclic compounds having a 1,3 diamino-functionality for use in the treatment of hiv infection
WO2015187295A2 (en) 2014-06-02 2015-12-10 Armo Biosciences, Inc. Methods of lowering serum cholesterol
US9932381B2 (en) 2014-06-18 2018-04-03 Sanofi Exendin-4 derivatives as selective glucagon receptor agonists
TWI677489B (zh) 2014-06-20 2019-11-21 美商基利科學股份有限公司 多環型胺甲醯基吡啶酮化合物之合成
WO2015200438A1 (en) 2014-06-24 2015-12-30 Eleven Biotherapeutics, Inc. High affinity antibodies against pcsk9
CA2955304C (en) 2014-07-16 2023-12-12 Sanofi Biotechnology Methods for treating high cardiovascular risk patients with hypercholesterolemia
JP2017528498A (ja) 2014-09-25 2017-09-28 アラクセス ファーマ エルエルシー Ｋｒａｓ ｇ１２ｃ変異体タンパク質のインヒビター
WO2016054388A1 (en) 2014-10-03 2016-04-07 University Of Pittsburgh - Of The Commonwealth System Of Higher Education Glutaminase inhibitors
WO2016055901A1 (en) 2014-10-08 2016-04-14 Pfizer Inc. Substituted amide compounds
NZ734082A (en) 2015-01-20 2019-01-25 Boehringer Ingelheim Animal Health Usa Inc Anthelmintic compounds, compositions and method of using thereof
WO2016127102A2 (en) 2015-02-06 2016-08-11 Ernesto Abel-Santos Inhibiting germination of clostridium perfringens spores to reduce necrotic enteritis
EA039310B1 (ru) 2015-02-26 2022-01-12 Санофи Байотекнолоджи Способы снижения сердечно-сосудистого риска
BR112017019378A2 (pt) 2015-03-18 2019-02-19 Zealand Pharma A/S análogos de amilina
EP3271405A1 (en) 2015-03-20 2018-01-24 Aarhus Universitet Inhibitors of pcsk9 for treatment of lipoprotein metabolism disorders
DK3283507T3 (da) 2015-04-16 2020-01-02 Zealand Pharma As Acyleret glucagonanalog
HK1257929A1 (zh) 2015-11-06 2019-11-01 Gemphire Therapeutics Inc. 治疗混合性血脂异常
TW201731867A (zh) 2015-12-02 2017-09-16 賽諾菲公司 Ｆｇｆ２１變異體
AU2016366560A1 (en) 2015-12-11 2018-06-28 The Trustees Of The University Of Pennsylvania Gene therapy for treating familial hypercholesterolemia
MX381314B (es) * 2016-01-20 2025-03-12 Janssen Sciences Ireland Uc Pirimidinas sustituidas con arilo para su uso en la infeccion por virus influenza
HK1257556A1 (zh) 2016-02-26 2019-10-25 耀石治疗公司 对正接受降脂疗法的纯合型家族性高胆固醇血症患者的治疗
PL3429591T3 (pl) 2016-03-16 2023-07-17 Kura Oncology, Inc. Podstawione pochodne tieno[2,3-d]pirymidyny jako inhibitory meniny-mll i metody ich zastosowania
JP2019513802A (ja) 2016-04-14 2019-05-30 ルシー マイケル 組み合わせ組成物およびその使用方法
TW201808888A (zh) 2016-05-05 2018-03-16 嘉來克生命科學有限責任公司 整合應激途徑之調節劑
WO2018007999A1 (en) 2016-07-08 2018-01-11 Staten Biotechnology B.V. Anti-apoc3 antibodies and methods of use thereof
US10960020B2 (en) 2016-09-15 2021-03-30 The Brigham And Women's Hospital, Inc. Modulation of PCSK9 and LDLR through DRP1 inhibition
EP4397311A3 (en) 2016-10-18 2024-10-16 Novartis AG Methods for preventing cardiovascular events through proprotein convertase subtilisin kexin 9 (pcsk9) protein reduction
US20200038481A1 (en) 2016-11-10 2020-02-06 Csl Limited Reconstituted high density lipoprotein treatment of myocardial infarction
JOP20190112A1 (ar) 2016-11-14 2019-05-14 Amgen Inc علاجات مدمجة لتصلب الشرايين، شاملة مرض قلبي وعائي تصلبي
WO2018106820A1 (en) 2016-12-07 2018-06-14 Kura Oncology, Inc. Methods of promoting beta cell proliferation
WO2018106818A1 (en) 2016-12-07 2018-06-14 Kura Oncology, Inc. Methods of promoting beta cell proliferation
AR110351A1 (es) 2016-12-13 2019-03-20 Bristol Myers Squibb Co COMPUESTOS DE HETEROARILO SUSTITUIDOS CON FOSFINÓXIDO ALQUILAMIDA COMO MODULADORES DE RESPUESTAS DE IL-12, IL-23 Y/O IFNa
PE20191716A1 (es) 2017-02-08 2019-12-05 Bristol Myers Squibb Co Polipeptidos de relaxina modificada que comprenden un mejorador farmacocinetico y sus usos
CA3072274C (en) 2017-02-08 2024-01-02 Brooke Schumm Intra-operative radiation therapy capsule with cylindrical shell radiation containment shutter system
AR110988A1 (es) 2017-02-21 2019-05-22 Sanofi Sa Compuestos de azetidina como moduladores de gpr119 para el tratamiento de la diabetes, la obesidad, la dislipidemia y trastornos relacionados
WO2018165718A1 (en) * 2017-03-17 2018-09-20 Cardio Therapeutics Pty Ltd Heterocyclic inhibitors of pcsk9
WO2018175746A1 (en) 2017-03-24 2018-09-27 Kura Oncology, Inc. Methods for treating hematological malignancies and ewing's sarcoma
CN110506056A (zh) 2017-04-21 2019-11-26 斯塔滕生物技术有限公司 抗apoc3抗体和其使用方法
JP7252908B2 (ja) 2017-06-14 2023-04-05 トレベナ・インコーポレイテッド Ｓ１ｐ１活性を調節するための化合物およびその使用法
JP6928986B2 (ja) 2017-06-26 2021-09-01 深▲チェン▼市塔吉瑞生物医薬有限公司Ｓｈｅｎｚｈｅｎ ＴａｒｇｅｔＲｘ， Ｉｎｃ． キナーゼ活性を阻害するためのインダゾール系化合物、その組成物および使用
CN109384712B (zh) 2017-08-14 2021-05-07 北京宽厚医药科技有限公司 靶向nk1受体拮抗剂及其在化疗所致恶心、呕吐治疗中的应用
WO2019079701A1 (en) 2017-10-20 2019-04-25 Dana-Farber Cancer Institute, Inc. HETEROBIFUNCTIONAL COMPOUNDS HAVING IMPROVED SPECIFICITY FOR BRD4 BROMODOMAINE
JP2021501210A (ja) 2017-10-30 2021-01-14 モントリオール ハート インスティテュート 血漿コレステロールの上昇を処置する方法
PE20210119A1 (es) 2017-10-31 2021-01-19 Staten Biotechnology B V Anticuerpos anti-apoc3 y metodos de uso de estos
UY37957A (es) 2017-11-02 2019-05-31 Abbvie Inc Moduladores de la vía de estrés integrada
EA202091269A1 (ru) 2017-11-21 2020-08-07 Бристол-Маерс Сквибб Компани Сульфон-, пиридин-, алкил-, амид-замещенные гетероарильные соединения
WO2019111225A1 (en) 2017-12-08 2019-06-13 Avaliv Therapeutics Compounds and methods for the treatment of non‑alcoholic steatohepatitis
SG11202005146VA (en) 2017-12-18 2020-06-29 Regeneron Pharma Bispecific antigen binding molecules that bind leptin receptor and/or gp130, and methods of use thereof
JP7466448B2 (ja) * 2018-01-17 2024-04-12 バーテックス ファーマシューティカルズ インコーポレイテッド Ｄｎａ－ｐｋ阻害剤
US11513131B2 (en) 2018-01-22 2022-11-29 Global Genomics Group, LLC Low density lipoprotein triglycerides (LDL-TG) as a biomarker of cardiovascular disease and uses thereof
WO2019147650A1 (en) 2018-01-23 2019-08-01 Gila Therapeutics, Inc. Peptide yy pharmaceutical formulations, compositions, and methods
CA3093469A1 (en) 2018-03-09 2019-09-12 The Brigham And Women's Hospital, Inc. Combination therapy for cardiovascular diseases
CN111936486B (zh) 2018-03-22 2023-09-22 百时美施贵宝公司 用作IL-12、IL-23和/或IFNα响应的调节剂的包含吡啶的杂环化合物
CN110384801B (zh) 2018-04-20 2021-09-14 中国科学院上海药物研究所 miRNA552簇的微小RNA在治疗LDLC相关代谢性疾病中的应用
ES2969982T3 (es) 2018-04-24 2024-05-23 Vertex Pharma Compuestos de pteridinona y usos de los mismos
US20190374526A1 (en) 2018-06-06 2019-12-12 Merck Sharp & Dohme Corp. Substituted Heterocyclic Compounds as Inhibitors of PRDM9
US11442072B2 (en) 2018-07-10 2022-09-13 Jenny and Antti Wihuri Foundation Method for measuring LDL aggregation
US11254660B2 (en) 2018-08-31 2022-02-22 Pfizer Inc. Combinations for treatment of NASH/NAFLD and related diseases
KR20210070300A (ko) 2018-10-03 2021-06-14 스태튼 바이오테크놀로지 비.브이. 사람 및 시노몰구스 ApoC3에 대해 특이적인 항체 및 이의 사용 방법
JP7631193B2 (ja) 2018-10-22 2025-02-18 アルミス インコーポレイテッド Ｔｙｋ２阻害剤およびその使用
KR20260037169A (ko) 2018-11-09 2026-03-17 노파르티스 아게 apo(a)를 표적화하는 콘쥬게이션된 안티센스 화합물로 심혈관 사건의 위험을 감소시키는 방법
US12399188B2 (en) 2018-12-06 2025-08-26 Zora Biosciences Oy Biomarkers for cardiovascular events
BR112021013807A2 (pt) 2019-01-18 2021-11-30 Astrazeneca Ab Inibidores de pcsk9 e seus métodos de uso
CN111484480B (zh) 2019-01-29 2023-08-11 上海翰森生物医药科技有限公司 一种多环类衍生物抑制剂、其制备方法和应用
CA3128368A1 (en) 2019-02-01 2020-08-06 Memorial Sloan Kettering Cancer Center Senolytic car-t cells targeting upar, a cell surface and secreted senescence biomarker
US20200390858A1 (en) 2019-04-17 2020-12-17 Ngm Biopharmaceuticals, Inc. Combination Therapy for Modulating Bile Acid Homeostasis and Treatment of Bile Acid Disorders and Diseases
WO2020234726A1 (en) 2019-05-20 2020-11-26 Pfizer Inc. Combinations comprising benzodioxol as glp-1r agonists for use in the treatment of nash/nafld and related diseases
WO2021119321A1 (en) 2019-12-10 2021-06-17 Regeneron Pharmaceuticals, Inc. Use of a pcsk9 inhibitor to treat homozygous familial hypercholesterolemia
WO2021209808A1 (en) 2020-04-16 2021-10-21 Abionyx Pharma Sa Cer-001 therapy for treating kidney disease
CN113713107B (zh) 2020-05-26 2022-09-23 中国科学院上海药物研究所 miRNA552簇的微小RNA在治疗糖脂代谢病中的应用
CA3179316A1 (en) 2020-05-29 2021-12-02 Andrew W. HAMER Pcsk9 inhibitors and methods of use thereof to treat cholesterol-related disorders
WO2021250069A1 (en) 2020-06-10 2021-12-16 Christian-Albrechts-Universität Zu Kiel Pharmaceutical compound for the treatment of atherosclerotic cardiovascular disease
US20240002354A1 (en) 2020-08-05 2024-01-04 Rezubio Pharmaceuticals Co., Ltd Antidiabetic compounds and compositions
EP4243805A1 (en) 2020-08-07 2023-09-20 Gbiotech S.À.R.L. Combination therapies for treating coronavirus infection
US12472171B2 (en) 2020-08-19 2025-11-18 Biogen Ma Inc. Methods for treating hypercholesterolemia
KR20230069969A (ko) 2020-09-15 2023-05-19 리제너론 파마슈티칼스 인코포레이티드 통증에 대한 lepr 아고니스트의 사용
AU2020472970A1 (en) 2020-10-20 2023-06-22 Halo Therapeutics Ltd Agonists of free fatty acid receptor 1 and their use in diseases associated with said receptor
AU2021373780A1 (en) 2020-11-05 2023-06-08 Amgen Inc. METHODS FOR TREATING ATHEROSCLEROTIC CARDIOVASCULAR DISEASE WITH LPA-TARGETED RNAi CONSTRUCTS
EP4011877A3 (en) 2020-12-11 2023-01-11 Institut de Cardiologie de Montréal Method of treating elevated plasma cholesterol
US20240044924A1 (en) 2020-12-11 2024-02-08 Helsingin Yliopisto Method for determining a likelihood of a subject to respond to lipid lowering therapy
EP4294257B1 (en) 2021-02-22 2025-11-05 Regeneron Pharmaceuticals, Inc. Method for diagnosing and treating partial lipodystrophy
US20250281495A1 (en) 2021-02-25 2025-09-11 Icahn School Of Medicine At Mount Sinai Methods for inhibiting inflammation and progression of atherosclerotic plaques and cardiovascular events in patients with cerebro- and cardio-vascular disease
CA3212583A1 (en) 2021-03-27 2022-10-06 Daniel Gooding Compositions having improved bioavailability of therapeutics
AU2022299514A1 (en) 2021-06-24 2024-01-18 Sirnaomics, Inc. Products and compositions
AU2022297535A1 (en) 2021-06-25 2024-01-04 Amgen Inc. Treatment of cardiovascular disease with trem-1 antigen binding proteins
EP4370519A1 (en) 2021-07-14 2024-05-22 Eternygen UK Ltd. 5,6,7,8-tetrahydro-2,6- and 2,7-naphthyridine derivatives for use in the treatment of diseases responsive to citrate transporter modulation
WO2023052783A1 (en) 2021-09-30 2023-04-06 Sitryx Therapeutics Limited Novel compounds
WO2023079294A1 (en) 2021-11-05 2023-05-11 Sitryx Therapeutics Limited Phthalazine derivatives as pyruvate kinase modulators
JP2024546039A (ja) 2021-11-12 2024-12-17 シェンチェン ジンタイ テクノロジー カンパニー リミテッド アスパラギン酸誘導体並びに肝線維症及び非アルコール性肝炎などの代謝性疾患の治療におけるその使用
CN114277032A (zh) 2021-12-31 2022-04-05 华中科技大学同济医学院附属协和医院 一种低密度脂蛋白受体基因突变体及其应用
US20250223281A1 (en) 2022-01-14 2025-07-10 Rezubio Pharmaceuticals Co., Ltd Antidiabetic compounds and compositions
TW202345865A (zh) 2022-01-24 2023-12-01 大陸商上海舶望製藥有限公司 抑制LPA(Apo(a))蛋白表達的組合物和方法
CN116617390A (zh) 2022-02-11 2023-08-22 武汉大学 Asgr1抑制剂在促进胆固醇外排和治疗非酒精性脂肪性肝病中的应用
US20250177377A1 (en) 2022-03-11 2025-06-05 University Of Florida Research Foundation, Incorporated Targeting ptchd1 and neuronal cholesterol to enhance safety of opioid analgesics
US20230338419A1 (en) 2022-03-21 2023-10-26 The Trustees Of The University Of Pennsylvania Methods and apparatus for diagnosis and detection of cardiac allograft vasculopathy
CN116948030B (zh) 2022-04-25 2024-11-19 武汉大学 抗asgr1单克隆抗体及其应用
CN117045715B (zh) 2022-05-13 2025-06-06 浙江养生堂天然药物研究所有限公司 红肉苹果和樱桃李组合物及其在抗动脉粥样硬化方面的应用
CN115581694A (zh) 2022-11-10 2023-01-10 正大青春宝药业有限公司 洋川芎内脂i在制备治疗高血脂症药物中的应用
CN117180404A (zh) 2023-10-24 2023-12-08 清华大学 Cholesin在调节胆固醇稳态中的用途
CN117482076A (zh) 2023-11-24 2024-02-02 中国人民解放军陆军军医大学第二附属医院 甲硫氨酸类化合物在制备pcsk9抑制剂中的应用

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2008502736A (ja) 2004-06-09 2008-01-31 アバニール・ファーマシューティカルズ 高脂血症および関連疾患の治療のための複素環式誘導体
JP2011501952A (ja) 2007-10-26 2011-01-20 シェーリング コーポレイション 脂質障害およびコレステロール障害を治療するための抗ｐｃｓｋ９および方法
WO2011152508A1 (ja) 2010-06-04 2011-12-08 興和株式会社 光学活性ジベンジルアミン誘導体及びその製造方法
JP2022518016A (ja) 2019-01-18 2022-03-11 アストラゼネカ・アクチエボラーグ Ｐｃｓｋ９阻害剤及びその使用方法

Also Published As

Publication number Publication date
CA3125765A1 (en) 2020-07-23
IL284640B1 (en) 2024-12-01
EA202191892A1 (ru) 2022-02-24
CR20210441A (es) 2022-03-11
WO2020150473A2 (en) 2020-07-23
KR20250172693A (ko) 2025-12-09
CN119112897A (zh) 2024-12-13
LT3911648T (lt) 2025-01-10
HRP20241674T1 (hr) 2025-02-14
CO2021010312A2 (es) 2021-09-20
TWI852981B (zh) 2024-08-21
PH12021551686A1 (en) 2022-05-16
MA54261A (fr) 2022-04-27
US11248001B2 (en) 2022-02-15
JP2025041641A (ja) 2025-03-26
JP2022518015A (ja) 2022-03-11
PE20220138A1 (es) 2022-01-27
US20220220122A1 (en) 2022-07-14
JOP20210193A1 (ar) 2023-01-30
CN119060040A (zh) 2024-12-03
EP3911648A4 (en) 2022-10-26
FI3911648T3 (fi) 2025-01-10
US12552807B2 (en) 2026-02-17
EP3911648A2 (en) 2021-11-24
KR20210116548A (ko) 2021-09-27
JP2022116083A (ja) 2022-08-09
AU2020209215A1 (en) 2021-08-26
IL284640B2 (en) 2025-04-01
SMT202500013T1 (it) 2025-03-12
RS66416B1 (sr) 2025-02-28
CN113574055B (zh) 2024-07-23
EP4470609A2 (en) 2024-12-04
SI3911648T1 (sl) 2025-02-28
DK3911648T3 (da) 2025-01-13
IL284640A (en) 2021-08-31
CL2021001859A1 (es) 2022-01-14
CN119119022A (zh) 2024-12-13
EP3911648B1 (en) 2024-10-23
MX2021008533A (es) 2021-08-19
TW202446767A (zh) 2024-12-01
BR112021013807A2 (pt) 2021-11-30
PT3911648T (pt) 2025-01-10
PL3911648T3 (pl) 2025-03-10
US20200291041A1 (en) 2020-09-17
TW202043213A (zh) 2020-12-01
CN119119023A (zh) 2024-12-13
EP4470609A3 (en) 2025-03-12
SG11202107614PA (en) 2021-08-30
ECSP21060240A (es) 2021-09-30
KR102889907B1 (ko) 2025-11-25
WO2020150473A3 (en) 2021-02-04
AU2020209215B2 (en) 2023-02-02
HUE069590T2 (hu) 2025-03-28
CN113574055A (zh) 2021-10-29
MA54261B1 (fr) 2025-03-28
DOP2021000150A (es) 2021-08-31
ES3007652T3 (en) 2025-03-20

Similar Documents

Publication Publication Date Title
JP7128969B2 (ja) Ｐｃｓｋ９阻害剤及びその使用方法
JP2022518016A (ja) Ｐｃｓｋ９阻害剤及びその使用方法
KR101695582B1 (ko) 심혈관 질환을 치료하기 위한 n-피페리딘-3-일벤즈아미드 유도체
HK40120023A (en) Pcsk9 inhibitors and methods of use thereof
HK40119387A (zh) Pcsk9抑制剂及其使用方法
HK40120861A (zh) Pcsk9抑制剂及其使用方法
HK40064422A (en) 6’-[[(1s,3s)-3-[[5-(difluoromethoxy)-2-pyrimidinyl]amino]cyclopentyl]amino][1(2h),3’-bipyridin]-2-one as pcsk9 inhibitor and methods of use thereof
HK40064422B (en) 6’-[[(1s,3s)-3-[[5-(difluoromethoxy)-2-pyrimidinyl]amino]cyclopentyl]amino][1(2h),3’-bipyridin]-2-one as pcsk9 inhibitor and methods of use thereof
HK40119389A (zh) Pcsk9抑制剂及其使用方法
HK40119391A (zh) Pcsk9抑制剂及其使用方法
EA052598B1 (ru) Ингибиторы pcsk9 и способы их применения
EA047736B1 (ru) Ингибиторы pcsk9 и способы их применения
TWI921300B (zh) Pcsk9抑制劑及其使用方法

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20220325

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20220325

A871 Explanation of circumstances concerning accelerated examination

Free format text: JAPANESE INTERMEDIATE CODE: A871

Effective date: 20220325

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20220517

A871 Explanation of circumstances concerning accelerated examination

Free format text: JAPANESE INTERMEDIATE CODE: A871

Effective date: 20220517

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20220607

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20220816

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20220819

R150 Certificate of patent or registration of utility model

Ref document number: 7128969

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250